Boehringer Ingelheim Corporation's New Data to Show Viral Cure Rates in the Most Difficult to Treat Hepatitis C Patients
4/5/2012 9:16:32 AM
INGELHEIM, Germany--(BUSINESS WIRE)--Key data from Boehringer Ingelheim’s hepatitis C virus (HCV) clinical trial programme, HCVersoTM, focusing on interferon-free treatment, has been selected for inclusion in the official European Association for the Study of the Liver (EASL) press office activities. These data are one of five abstracts from a range of new Boehringer Ingelheim HCV data that have been accepted for presentation at the International Liver Congress (ILC)TM 2012, taking place 18th– 22nd April in Barcelona, Spain.
comments powered by